Open AccessIntegrated analysis of RNA and DNA from the phase III trial CALGB 40601 identifies predictors of response to trastuzumab-based neoadjuvant chemotherapy in HER2-positive breast cancer
Author(s) -
M. Tanioka,
C. Fan,
J.S. Parker,
K.A. Hoadley,
Z. Hu,
Y. Li,
T.M. Hyslop,
B.N. Pitcher,
M.G. Soloway,
P.A. Spears,
L.N. Henry,
S. Tolaney,
C.T. Dang,
I.E. Krop,
L.N. Harris,
D.A. Berry,
E.R. Mardis,
E.P. Winer,
C.A. Hudis,
L.A. Carey,
C.M. Perou
Publication year - 2018
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/x3db-4w28
Subject(s) - trastuzumab , oncology , breast cancer , medicine , chemotherapy , complete response , cancer